All In Biotech

Drug Trial Radar · NCT07951359

A First-in-human, Dose Escalation, and Expansion Study of BNT3211 for Participants With Advanced Solid Tumors

A Phase I/II, First-in-human, Open-label, Multi-site, Dose Escalation and Expansion Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BNT3211 in Participants With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

345

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Oct 2029

Study completion Mar 2030

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
Collaborators
BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
First posted
Nov 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is the first time BNT3211 will be tested in people. It will evaluate different dose levels of BNT3211 in adults to find suitable doses and to understand how safe the treatment is and how it may help people with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • BNT3211Biological

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A only - Occurrence of dose-limiting toxicities (DLTs) during the DLT evaluation periodTime frame: Up to 21 days from the initiation of first dose of BNT3211
  2. Number of participants with treatment emergent adverse events (TEAEs), Grade ≥3 TEAEs, serious adverse events (SAEs), treatment-related TEAEs, treatment-related Grade ≥3 TEAEs, and treatment-related SAEsTime frame: From first dose until 35 days after the last dose of BNT3211 (up to 36 months)
  3. Number of participants with dose interruptions, reductions, or discontinuations of study treatment due to TEAEsTime frame: From the first until the last dose of BNT3211 (up to 36 months)
  4. Part B only - Objective response rateTime frame: Up to 36 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.